ANTXAN2 Therapeutics, Inc.同业对比
AN2 Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTX本股 | $168M#7 | — | 2.2x#9 | — | — | 31.5%#4 | — | -46.3%#8 | — | — | — | — |
| WHWK | $182M#1 | — | 1.0x#7 | 25.5x#4 | -72.5%#6 | 67.7%#2 | -1601.1%#6 | -11.3%#6 | — | — | — | — |
| INO | $181M#2 | — | 41.4x#13 | 2769.2x#8 | -70.0%#5 | 20.6%#6 | -132871.3%#8 | -1944.6%#14 | -243.9%#3 | — | -25.5%#4 | — |
| TRDA | $178M#3 | — | 0.8x#5 | 7.0x#3 | -87.9%#7 | -319.0%#13 | -621.1%#4 | -61.6%#10 | — | — | -34.1%#6 | — |
| UPB | $176M#4 | — | 0.6x#3 | 61.6x#5 | 20.4%#2 | -128.4%#11 | -5618.8%#7 | -52.9%#9 | — | — | -87.6%#7 | — |
| CNTN | $170M#5 | — | 0.4x#1 | — | — | -194.5%#12 | — | -7.9%#5 | — | — | -27.1%#5 | — |
| SION | $169M#6 | — | 0.6x#2 | — | — | -22.0%#10 | — | -28.3%#7 | — | — | — | — |
| ORMP | $168M#8 | 1.0x#2 | 0.8x#6 | 84.2x#7 | — | 573.1%#1 | -754.4%#5 | 0.0%#2 | -4.4%#1 | — | 70.5%#2 | — |
| PEPG | $162M#9 | — | 1.4x#8 | — | — | 0.4%#7 | — | -75.0%#12 | — | — | — | — |
| MBRX | $158M#10 | 0.6x#1 | 13.6x#11 | — | — | 28.8%#5 | — | 289.6%#1 | — | — | — | — |
| MGNX | $156M#11 | — | 3.6x#10 | 1.0x#1 | -0.3%#4 | -11.4%#8 | -48.7%#1 | -0.2%#4 | — | — | 48.8%#3 | — |
| CUE | $154M#12 | — | 66.7x#14 | 5.6x#2 | 195.7%#1 | 34.6%#3 | -96.7%#2 | -1151.6%#13 | — | — | — | — |
| KRSA | $147M#13 | — | 28.9x#12 | 70.9x#6 | 3.7%#3 | -15.4%#9 | -239.8%#3 | -69.4%#11 | -69.1%#2 | — | 139.9%#1 | — |
| RNA | $145M#14 | — | 0.7x#4 | — | — | — | — | 0.0%#3 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议